Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

KYTH 74.98 0.00 (0.00%)
price chart
Investors Tracking Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)'s
Investors are following Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)'s stock movement, which recorded the first trade at 74.98 and was hovering around 74.98 lately.
Why Kythera Biopharmaceuticals, Inc. Stock Soared Today
What: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) shot up by 22% today after the company agreed to sell itself to Botox-maker Allergan (NYSE:AGN) for $75 per share, or $2.1 billion.
Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion  Bloomberg
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
What's happening: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) soared higher by as much as 20% ahead of a key FDA advisory panel committee meeting next week.
FDA staff backs injection to reduce double chin  Reuters
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH): Stock in the spotlight
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) has successfully managed to attain positive rating on its stock. Zacks planned a poll of sell-side experts after which the firm assigned N/A rating on company's stock.
Sell Kythera (KYTH) Stock, Another Biotech Ripoff
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) stock was halted Monday as an independent advisory committee reviewed its double-chin treatment, ATX-101.
Kythera Biopharmaceuticals Inc's (KYTH) Double-Chin Treatment Backed By ...  Bidness ETC
KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock  GlobeNewswire (press release)
Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
What: Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH), a clinical-stage biopharmaceutical company developing prescription products targeted at the aesthetic medicine market, jumped by as much as 12% after the company announced it had ...
Kythera Regains ATX-101 from Bayer
Kythera Regains ATX-101 from Bayer - Analyst Blog  NASDAQ
Related articles »  
West Oak Capital Eliminates Stake in Kythera Biopharmaceuticals Inc (KYTH)
Kythera Biopharmaceuticals logo West Oak Capital eliminated its stake in shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Kythera Biopharmaceuticals Inc (KYTH) Position Sold by West Oak Capital  Zolmax
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Recent Analyst Updates  Risers & Fallers
Allergan (AGN), KYTHERA Biopharma (KYTH) Enter Amended Merger; Will Now be All ...
Allergan (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to ...
Allergan Changes Its $2.1 Billion Deal for Kythera to All Cash  Wall Street Journal
Allergan adjusted profit beats views as sales jump  MarketWatch
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of KYTHERA Biopharmaceuticals, Inc. (“KYTHERA” or the “Company”) (NASDAQ GS: KYTH) regarding possible breaches of fiduciary duties and ...
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First ...  GlobeNewswire (press release)
Kythera Biopharmaceuticals Stock Climbs On Acquisition News  CNA Finance (press release)
Price Target For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Stock
Wall Street analysts have revealed their short-term price target on Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) stock, and this target is set at $N/A.